Please ensure Javascript is enabled for purposes of website accessibility

Aurora Cannabis Stock Soars on Q1 Results

By Eric Volkman – Nov 9, 2020 at 10:51PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Revenue was better than expected, despite a quarter-over-quarter dip.

Already high on recent state legalization initiatives and a potentially more weed business-friendly presidential administration, marijuana stock investors got another blast of good news on Monday. A bellwether company in the industry, Aurora Cannabis (ACB -2.40%) delivered better-than-expected quarterly results, at least on the top line.

For Aurora's Q1 of fiscal 2021, the company's net revenue was $67.8 million Canadian ($52.2 million), down by 1% from the previous quarter, and 10% lower on a year-over-year basis.

The company confusingly presented several different profitability metrics. The one it favors, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA), deepened by 79% quarter over quarter to CA$57.9 million ($44.5 million), a figure that includes expenses related to recent restructuring activities. The Q1 2020 result was CA$39.7 million ($30.5 million).

Hand holding a burning marijuana cigarette.

Image source: Getty Images.

In spite of those erosions, investors were cheered by the fact that analysts tracking the stock collectively estimated it would book only CA$63.6 million ($48.9 million) in revenue.

Describing the quarter as a "transitional," one on the path to liquidity and stability, CEO Miguel Martin didn't hesitate to point out several reasons for investors to be cheerful.

He was quoted as saying that "We remain the leader by revenue in the high-margin Canadian medical market, our international medical business experienced more than 40% net revenue growth this quarter, and our CBD [cannabidiol] brand Reliva is No. 1 ranked by Nielsen in the U.S. CBD sector."

In its release, the company added that it aims to reach positive adjusted EBITDA next quarter.

Investors are certainly looking on the bright side of Aurora's results. They bid the company's stock up by 14.5% on Monday, crushing the comparatively modest gain of the S&P 500 index.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aurora Cannabis Stock Quote
Aurora Cannabis
ACB
$1.22 (-2.40%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.